Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 ORYZF | Healthcare | $3.10 | 0.00 | $211.95M | -75.19 | ― | Moderate Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ORYZF | Oryzon Genomics SA | 3.10 | -1.27 | -29.08% |
| Name | Price | % Change | |
|---|---|---|---|
| ORYZF | $3.10 | -29.08% |
Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Oryzon Genomics SA, with a price target of $10.00. Jason McCarthy has given his Buy rating due to a
The latest update is out from Oryzon Genomics SA ( ($ES:ORY) ). R&D investments reached €14.1 million in the first nine months of 2026, up 71.0% from €8.3 million in
Oryzon Genomics (ORN) is scheduled to report 3rd quarter earnings on 10/22/2026. Regarding Q3 estimates, Wall Street analysts expect Oryzon Genomics to post earnings of -€0.07 per share. Last quarter,
Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Oryzon Genomics SA, retaining the price target of $10.00. Jason McCarthy has given his Buy rating due to a
An announcement from Oryzon Genomics SA ( ($ES:ORY) ) is now available. Oryzon Genomics has updated its accounting treatment for capitalization of financial expenses related to development intangibles financed by
Oryzon Genomics SA ( ($ES:ORY) ) has shared an announcement. Oryzon Genomics SA has reported the deregistration of 2,390,000 shares that previously carried double voting rights under its loyalty share
Oryzon Genomics SA ( ($ES:ORY) ) has provided an update. Oryzon Genomics SA has completed and fully paid up a share capital increase amounting to €12,000,001.50, with the deed of
An announcement from Oryzon Genomics SA ( ($ES:ORY) ) is now available. Oryzon Genomics has completed an accelerated private placement, raising approximately €12 million through a capital increase by issuing
Oryzon Genomics SA ( ($ES:ORY) ) has provided an update. Oryzon Genomics SA announced that all resolutions presented at its ordinary general shareholders’ meeting held on June 26, 2026, were
An announcement from Oryzon Genomics SA ( ($ES:ORY) ) is now available. Oryzon Genomics has approved a cash capital increase of up to €10 million, potentially rising to €15 million,
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| ORYZF | buy | Reiterated | Nov 10, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| ORYZF | Mar 4, 2027TBA | $211.95M | $-0.07 | $0.00 | 2.31 | -75.19 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
